Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 108
Summary
- Conditions
- Blood Protein Disorders
- Analgesics
- Analgesics Non-narcotic
- Antineoplastic Agents
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Vascular Diseases
- Cardiovascular Diseases
- "Hematologic Diseases"
- Multiple Myeloma
- Sensory System Agents
- Hemorrhagic Disorders
- Hemostatic Disorder
- Immune System Diseases
- Immunoproliferative Disorders
- Lymphoproliferative Disorders
- Neoplasms by Histologic Type
- Neoplasm, Plasma Cell
- Paraproteinemias
- Neoplasms
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Sequential AssignmentIntervention Model Description: The study will utilize a 3+3 open label design, and will enroll up to three dosing cohorts of CYNK-001 given on Day 2 or Days 2, 7, 14 post ASCT. Once MTD has been determined, the Expansion cohort will commence.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04309084
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon